Preview

Медицинский Совет

Расширенный поиск

СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ ОБ ЭТИОПАТОГЕНЕЗЕ, КЛИНИКЕ И ТЕРАПИИ ДИСМЕНОРЕИ

https://doi.org/10.21518/2079-701X-2017-2-112-115

Полный текст:

Аннотация

Статья посвящена актуальной для женщин репродуктивного возраста теме – дисменорее. Оказывая влияние не только на состояние здоровья женщин, но и на различные стороны их жизнедеятельности, дисменорея является и медицинской, и социальной проблемой. Применение нестероидных противовоспалительных препаратов при данном состоянии – эффективное средство патогенетической терапии, значительно повышающее качество жизни женщин.

Об авторах

А. Л. Унанян
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия

д.м.н., профессор



И. С. Сидорова
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
академик РАН, д.м.н., профессор


Ю. И. Чушков
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
к.м.н.


А. Д. Никонец
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия


Д. В. Бабурин
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия


Список литературы

1. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update, 2015 Nov-Dec, 21(6): 762-78.

2. Osayande AS, Mehulic S. Diagnosis and initial management of dysmenorrhea. Am Fam Physician, 2014 Mar 1, 89(5): 341-6.

3. Mrugacz G, Grygoruk C, Sieczyński P, Grusza M, Bołkun I, Pietrewicz P. Etiopathogenesis of dysmenorrhea. Med Wieku Rozwoj. 2013 Jan-Mar, 17(1): 85-9.

4. Ortiz MI. Primary dysmenorrhea among Mexican university students: prevalence, impact and treatment. Eur J Obstet Gynecol Reprod Biol, 2010, 152: 73–77.

5. Wong LP. Attitudes towards dysmenorrhoea, impact and treatment seeking among adolescent girls: a rural school-based survey. Aust J Rural Health, 2010, 19: 218–223.

6. Pitangui AC, Gomes MR, Lima AS, Schwingel PA, Albuquerque AP, de Araujo RC. Menstruation disturbances: prevalence, characteristics, and effects on the activities of daily living among adolescent girls from Brazil. J Pediatr Adolesc Gynecol, 2013, 26: 148–152.

7. Ayan M, Sogut E, Tas U, Erdemir F, Sahin M, Suren M, Kaya Z, Demirturk F. Pain levels associated with renal colic and primary dysmenorrhea: a prospective controlled study with objective and subjective outcomes. Arch Gynecol Obstet, 2012, 286: 403–409.

8. Jones AE. Managing the pain of primary and secondary dysmenorrhoea. Nurs Times, 2004, 100: 40–43.

9. Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev, 2014, 36: 104-13.

10. Berkley KJ, McAllister SL. Don’t dismiss dysmenorrhea! Pain, 2011, 152: 1940–1941.

11. Pejčić A, Janković S. Risk factors for dysmenorrhea among young adult female university students. Ann Ist Super Sanita, 2016 Jan-Mar, 52(1): 98-103.

12. Ju H, Jones M, Mishra G. A U-Shaped Relation ship between Body Mass Index and Dysmeno rrhea: A Longitudinal Study. PLoS One, 2015 Jul 28, 10(7).

13. Iacovides S., Baker FC, Avidon I, Bentley A. Women with dysmenorrhea are hypersensitive to experimental deep muscle pain across the menstrual cycle. J Pain, 2013 Oct, 14(10): 1066-76.

14. Vincent K, Warnaby C, Stagg CJ, Moore J, Kennedy S, Tracey I. Dysmenorrhoea is associated with central changes in otherwise healthy women. Pain, 2011, 152: 1966–1975.

15. Ye R, Wang S, Li Y, Wu R, Pei J, Wang J, Zhao Z. Primary dysmenorrhea is potentially predictive for initial orthodontic pain in female patients. Angle Orthod, 2014 May, 84(3): 424-9.

16. Juang CM, Yen MS, Twu NF, Horng HC, Yu HC, Chen CY. Impact of pregnancy on primary dysmenorrhea. Int J Gynaecol Obstet, 2006 Mar, 92(3): 221-7.

17. Hayaishi O, Matsumura H. Prostaglandins and sleep. Adv Neuroimmunol, 1995, 5: 211–216.

18. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol, 2006, 108: 428–441.

19. Coco AS. Primary dysmenorrhea. Am Fam Physician, 1999, 60: 489–496.

20. Nigam S, Benedetto C, Zonca M, Leo-Rossberg I, Lübbert H, Hammerstein J. Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids, 1991, 4(3): 137-41.

21. Harel Z. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea. J Pediatr Adolesc Gynecol, 2004, 17: 75–79.

22. Altunyurt S, Gol M, Altunyurt S, Sezer O, Demir N. Primary dysmenorrhea and uterine blood flow: a color Doppler study. J Reprod Med, 2005, 50: 251–255.

23. Loram LC, Mitchell D, Skosana M, Fick LG. Tramadol is more effective than morphine and amitriptyline against ischaemic pain but not thermal pain in rats. Pharmacol Res, 2007, 56: 80–85.

24. Tu CH, Niddam DM, Chao HT, Liu RS, Hwang RJ, Yeh TC, Hsieh JC. Abnormal cerebral metabolism during menstrual pain in primary dysmenorrhea. Neuroimage, 2009, 47: 28–35.

25. Tu CH, Niddam DM, Chao HT, Chen LF, Chen YS,WuYT, Yeh TC, Lirng JF, Hsieh JC. Brain morphological changes associated with cyclic menstrual pain. Pain, 2010, 150: 462–468.

26. Ma H, Hong M, Duan J, Liu P, Fan X, Shang E, Su S, Guo J, Qian D, Tang Y. Altered cytokine gene expression in peripheral blood monocytes across the menstrual cycle in primary dysmenorrhea: a case-control study. PLoS One, 2013, 8.

27. Iacovides S, Avidon I, Bentley A, Baker FC. Reduced quality of life when experiencing menstrual pain in women with primary dysmenorrhea. Acta Obstet Gynecol Scand, 2014, 93: 213–217.

28. Driver HS, Baker FC. Menstrual factors in sleep. Sleep Med Rev, 1998, 2: 213–229.

29. Chantler I, Mitchell D, Fuller A. Actigraphy quantifies reduced voluntary physical activity in women with primary dysmenorrhea. J Pain, 2009, 10: 38–46.

30. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med, 2003, 163: 2433–2445.

31. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum, 2008, 37: 339–352.

32. Engeler DS, Baranowski AP, Dinis-Oliveira P, Elneil S, Hughes J, Messelink EJ, van Ophoven A, Williams AC. The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol, 2013 Sep, 64(3): 431-9.

33. Ortiz MI, Cortés-Márquez SK, Romero-Quezada LC, Murguía-Cánovas G, Jaramillo-Díaz AP.

34. Effect of a physiotherapy program in women with primary dysmenorrhea. Eur J Obstet Gynecol Reprod Biol, 2015 Nov, 194: 24-9.

35. Yu S, Yang J, Yang M, Gao Y, Chen J, Ren Y, Zhang L, Chen L, Liang F, Hu Y. Application of acupoints and meridians for the treatment of primary dysmenorrhea: a data mining-based literature study. Evid Based Complement Alternat Med, 2015, 752194.

36. Shah M, Monga A, Patel S, Shah M, Bakshi H. The effect of hypnosis on dysmenorrhea. Int J Clin Exp Hypn, 2014, 62(2): 164-78.

37. Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea. BJOG, 2005 Apr, 112(4): 466-9.

38. Zekavat OR, Karimi MY, Amanat A, Alipour F. A randomised controlled trial of oral zinc sulphate for primary dysmenorrhea in adolescent females. Aust N Z J Obstet Gynaecol, 2015 Aug, 55(4): 369-73.

39. Lindh I, Milsom I. The influence of intrauterine contraception on the prevalence and severity of dysmenorrhea: a longitudinal population study. Hum Reprod, 2013, 28: 1953–60.

40. Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev, 2001.

41. Ruoff G, Lema M. Strategies in pain management: new and potential indications for COX-2 specific inhibitors. J Pain Symptom Manage, 2003, 25: S21–S31.

42. Strowitzki T, Kirsch B, Elliesen J. Efficacy of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen in women with moderateto-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care, 2012, 38: 94–101.

43. Albright M, Rani S, Gavagan T. HelpDesk answers: do hormonal contraceptives lead to weight gain? J Fam Pract, 2015 Jun, 64(6): 371-2.

44. Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception, 2010, 81: 185–196.

45. Kaplan Ö, Nazıroğlu M, Güney M, Aykur M. Nonsteroidal anti-inflammatory drug modulates oxidative stress and calcium ion levels in the neutrophils of patients with primary dysmenorrhea. J Reprod Immunol, 2013 Dec, 100(2): 87-92.

46. Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev, 2010 Jan 20, (1): CD001751.

47. Langford RM, Evans N. Developments in specific cyclooxygenase therapy for acute pain. Acute Pain, 2002, 4: 1–4.

48. Campbell MA, McGrath PJ. Non-pharmacologic strategies used by adolescents for the management of menstrual discomfort. Clin J Pain, 1999, 15: 313–320.

49. Sherif BQ, Al-Zohyri AM, Shihab SS. Effects of Some Non Steroidal Anti-inflammatory Drugs on Ovulation in Women with Mild Musculoskeletal Pain (A Clinical Study) IOSR. Journal of Pharmacy and Biological Sciences (IOSR-JPBS), 2014 Jul-Aug, 9(Issue 4 Ver. IV): 43-49 www.iosrjournals.org.

50. Инструкция к применению препарата Амелотекс http: //www.sotex.ru/production/catalog/detail.php?ELEMENT_ID=4268


Просмотров: 122


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)